| Budget Amount *help |
¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1986: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1985: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Research Abstract |
Antigens reactive with anti-pancreatic oncofetal antigen(POA, Nishida, K. et al, Hepatogastroenterol., 28, 102, 1981) were separated from the ascites of the patient with pancreatic cancer by gel filtration of ACA34. Molecular weight of this antigen was estimated at 500KD-600KD by Sepharose 4B gel filtration. Guinea pig were immunized to obtain polyclonal antibodies for the first antibodies of an enzyme immunoassay system for screening. Balb/c mice were immunized and their spleen cells were fused with X63.Ag8.653 mouse myeloma cell line. After cloning and two steps of screening, several clones were expanded in ascitic forms.
Subclass of PM4, one of the monoclonal antibodies, was Ig <G_1> . IgG fraction of PM4 was purified by DEAE cellulose column chromatography and used for the second antibody in the assay system. When we settled a cut-off value 77.2 unit/ml, mean + 2SD of normal subjects, percentages of antigen-positive patients in sera were as follows; 72.7 % of pancreatic cancer, 56.7 % of gastric cancer, 58.0 % of colorectal cancer, 33.3 % of esophageal cancer, 68.8 % of hepatoma, 55.6 % of gall bladder cancer, 53.8 % of lung cancer, 55.0 % of malignant lymphoma, 62.5 % of acute myelogenous leukemia, and 50.0 % of multiple myeloma. Percentages of antigen-positive patients increased as the progress of the stages in gastric cancers. PM4 did not react with AFP, CEA, ferritin, CA19-9 and several other tumor markers. There were little correlations between PM4 and AFP, or PM4 and CA19-9. Localization of antigens was studied by a immunochemical staining method and antigens were stained in the cytoplasma of pancreatic cancer cells.
From these data, it was concluded that combination analysis with other tumor markers might be useful in the serodiagnosis of cancer patients.
|
